These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Altimmune (ALT) reported a narrower-than-expected Q2 loss of $0.27 per share, with minimal sales, yet its shares gained 5.7%. This positive market reaction was primarily driven by CEO Vipin Garg's update on the promising Phase 2b results for Pemvidutide, which demonstrated robust MASH effects and weight loss, positioning the drug for an End-of-Phase 2 FDA meeting. While analysts from B. Riley and UBS maintained Buy ratings, they concurrently lowered their price targets, signaling continued confidence in the pipeline despite some re-evaluation.

Analysis

Altimmune, Inc. reported a second-quarter loss of $0.27 per share, outperforming market expectations of a $0.32 per share loss, alongside negligible quarterly sales of $5,000. Despite the net loss, the company's shares appreciated 5.7%, indicating that investor focus is predominantly on its clinical pipeline rather than current financial performance. The positive market sentiment is directly attributable to the company's update on pemvidutide, its lead drug candidate, which demonstrated robust efficacy for MASH and meaningful weight loss in its Phase 2b trial. The company is now advancing towards a pivotal End-of-Phase 2 meeting with the FDA, with full 48-week trial data anticipated in the fourth quarter. Analyst sentiment remains bullish, with B. Riley Securities, UBS, and HC Wainwright & Co. all maintaining 'Buy' ratings. However, this optimism is tempered by downward price target revisions from B. Riley (to $18) and UBS (to $24), suggesting a recalibration of valuation expectations even as the fundamental outlook on the drug remains positive.

Key Decisions for Investors

• Investors should recognize that Altimmune's valuation is driven almost exclusively by the clinical and regulatory progress of its drug candidate pemvidutide, not its current earnings, making pipeline updates the primary stock catalyst.
• Monitor the company's upcoming End-of-Phase 2 meeting with the FDA and the release of full 48-week trial data in the fourth quarter, as these are critical near-term milestones that will significantly impact future valuation.
• While the consensus 'Buy' ratings are a strong positive signal, the lowered price targets from two analysts suggest it may be prudent to factor in potentially moderated near-term upside expectations despite the promising clinical results.